Introduction
Haem is synthesised in all animal cells from succinyl CoA and glycine by a sequence of reactions catalysed by eight enzymes.1 Absence of any one of these enzymes is incompatible with life because haem is an essential component of respiratory proteins. Partial deficiencies occur, however, and cause disease (table 1) . 12 The activity of 5-aminolaevulinate (ALA) synthase, the first and rate controlling enzyme of the pathway, is decreased in the bone marrow in hereditary sideroblastic anaemias,3 while deficiency of each of the subsequent enzymes produces a particular type of porphyria (table 1) .1 2 The enzyme defect in each porphyria is inherited (table 1), except in type I porphyria cutanea tarda which appears to be an acquired disorder. The clinical features and laboratory diagnosis of the porphyrias have been reviewed.' 2 Genes or cDNAs have now been isolated and characterised for all but two of the human enzymes (table 2). These advances have been followed rapidly by identification of mutations in the corresponding diseases and by the application of DNA techniques to the management of families with these conditions. This review summarises current information about the molecular genetics of each disorder. 20 and ,B globin genes,2' contains sequences that interact with the trans-acting erythroid specific factors, GATA-1 and NF-E2, and regulate transcription during erythroid differentiation.5 The 5' untranslated region (UTR) of ALAS2 mRNA, unlike ALAS 1 mRNA, contains a sequence structure motif that closely resembles the iron responsive elements (IREs) found in the 5' UTR of ferritin mRNA and the 3' UTR of transferrin receptor mRNA.i22 Iron deficiency leads to high affinity binding of an IRE-binding protein to these elements with consequent inhibition of translation of ALAS2 and ferritin mRNAs and stabilisation of transferrin receptor mRNA,22 a mechanism that allows co-ordination of protoporphyrin formation with iron supply. The presequences of both ALAS isoenzymes also contain a conserved, haem regulatory motif which is involved in inhibition by haem of their transport into 24 mitochondria. 4 The discovery that ALAS2 maps to the X chromosome prompted a search for muta- 10 by glutamine or tryptophan with one mutation (G-+A at base position 500; R1 67Q) being more frequent than the others.3031 These mutations severely impair but do not abolish enzyme activity.32 Interestingly, the only two unrelated cases of homozygous AIP that have been reported were both compound heterozygotes for three of the CRIM positive exon 10 mutations,3 suggesting that their frequency may be higher than the prevalence of overt CRIM positive AIP would indicate. The structure of PBG deaminase is highly conserved with over 45% amino acid sequence identity between the Escherichia coli and human enzymes. X-ray analysis of the crystal structure of the E coli enzyme shows that the arginine residues corresponding to these two residues in exon 10 of human PBGD and a third one in exon 3, which is the site of another CRIM positive mutation (R26H) in AIP,34 form salt bridges with the acidic side chains of the dipyrro- Most patients are compound heterozygotes and no clear relationship between genotypes and the two different phenotypes has yet been established. Homozygotes for the C73R mutation, however, are severely affected while patients with a T228M mutation of one allele seem to have less severe disease.67 The infantile form of congenital erythropoietic porphyria is probably the only type of porphyria for which prenatal diagnosis should be available. DNA analysis should allow this to be achieved with greater precision than is currently possible.
The future Several important problems in the pathogenesis and management of inherited disorders of haem biosynthesis now seem likely to be solved by the application of recombinant DNA methods. In the acute hepatic porphyrias, the way towards much more accurate detection of gene carriers is already clear from studies on AIP; similar progress for variegate porphyria and hereditary coproporphyria should follow once the relevant genes have been cloned. The influence of genetic factors in determining phenotypic variation and differences between families in the penetrance of the autosomal dominant porphyrias remains to be explored. For example, genes that directly or indirectly influence the inducibility of ALAS 1 in the liver may be important determinants of susceptibility to acute porphyria. Finally, transgenic animal experiments may help to solve outstanding problems, such as the mechanism of the acute porphyric attack, and lead to new treatments.
